Tulsa Wealth Advisors INC Takes Position in Edwards Lifesciences Corporation $EW

Tulsa Wealth Advisors INC bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 9,430 shares of the medical research company’s stock, valued at approximately $804,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. JPL Wealth Management LLC purchased a new stake in Edwards Lifesciences in the 3rd quarter worth $25,000. MV Capital Management Inc. purchased a new position in Edwards Lifesciences during the fourth quarter valued at $26,000. Kemnay Advisory Services Inc. purchased a new position in Edwards Lifesciences during the fourth quarter valued at $27,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $28,000. Finally, Hilton Head Capital Partners LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $28,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on EW. BTIG Research upped their price target on shares of Edwards Lifesciences from $98.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, April 24th. TD Cowen reiterated a “buy” rating and issued a $104.00 price objective (up from $97.00) on shares of Edwards Lifesciences in a report on Tuesday, June 2nd. Mizuho set a $95.00 price objective on Edwards Lifesciences and gave the stock an “outperform” rating in a research note on Monday, April 13th. Evercore reissued an “outperform” rating and set a $93.00 target price on shares of Edwards Lifesciences in a report on Friday, April 24th. Finally, Truist Financial set a $90.00 target price on Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, April 24th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $95.96.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $87.51 on Friday. The company has a fifty day simple moving average of $83.39 and a 200-day simple moving average of $83.14. The firm has a market capitalization of $50.39 billion, a price-to-earnings ratio of 46.55, a PEG ratio of 2.19 and a beta of 0.87. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $89.60.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.05. The firm had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The company’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period last year, the firm posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, equities analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total value of $1,040,520.00. Following the transaction, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at $3,177,507.96. This trade represents a 24.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the transaction, the vice president owned 98,611 shares in the company, valued at approximately $8,521,962.62. This represents a 19.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 81,038 shares of company stock worth $6,683,255 in the last quarter. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.